<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Triple positivity (positive <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">Anticoagulant</z:chebi>, anticardiolipin and anti β2-glycoptrotein I antibodies) identifies the pathogenic autoantibody (anti Domain I of β2-glycoptroteinI) that is present in patients with definite <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid Syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>This is supported by the fact that aβ2GPI antibodies obtained by affinity purification in these patients possess LA activity </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, patients and carriers of this profile carry a much higher risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> and pregnancy loss than APS patients with positivity for only one of the tests </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, very different risk categories exist among patients with APS as well as among carriers of aPL </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical studies and interventional trials should first take these high risk subjects into consideration </plain></SENT>
</text></document>